FY2027 EPS Estimates for Insulet Lifted by Leerink Partnrs

Insulet Co. (NASDAQ:PODD - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2027 earnings per share estimates for shares of Insulet in a research note issued to investors on Thursday, May 8th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings per share of $7.10 for the year, up from their previous estimate of $6.89. The consensus estimate for Insulet's current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet's FY2028 earnings at $8.86 EPS and FY2029 earnings at $10.58 EPS.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. During the same period last year, the company posted $0.73 EPS. The business's quarterly revenue was up 28.8% on a year-over-year basis.

Several other research firms have also commented on PODD. Wolfe Research lowered Insulet from an "outperform" rating to a "peer perform" rating in a research report on Tuesday, April 29th. StockNews.com lowered Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Stifel Nicolaus lifted their target price on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Oppenheimer lifted their target price on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, Royal Bank of Canada assumed coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $303.81.

Insulet Trading Up 20.8%

NASDAQ:PODD opened at $310.42 on Monday. The business's 50-day moving average is $257.45 and its two-hundred day moving average is $263.88. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a 12 month low of $160.19 and a 12 month high of $312.80. The firm has a market capitalization of $21.84 billion, a PE ratio of 53.61, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26.

Insider Buying and Selling at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.47% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insulet

A number of hedge funds have recently made changes to their positions in PODD. Principal Financial Group Inc. raised its holdings in shares of Insulet by 4.0% during the third quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier's stock valued at $20,065,000 after buying an additional 3,355 shares during the last quarter. Nordea Investment Management AB raised its holdings in Insulet by 6.3% during the fourth quarter. Nordea Investment Management AB now owns 6,078 shares of the medical instruments supplier's stock worth $1,598,000 after purchasing an additional 359 shares in the last quarter. Graypoint LLC raised its holdings in Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock worth $243,000 after purchasing an additional 47 shares in the last quarter. Czech National Bank raised its holdings in Insulet by 6.5% during the fourth quarter. Czech National Bank now owns 15,209 shares of the medical instruments supplier's stock worth $3,971,000 after purchasing an additional 926 shares in the last quarter. Finally, CHICAGO TRUST Co NA bought a new stake in Insulet during the fourth quarter worth approximately $294,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.